Special Issue "Antiviral Agents"
Deadline for manuscript submissions: closed (30 November 2019).
A printed edition of this Special Issue is available here.
Interests: virology; antivirals; innate immunity; virus–host interactions; virus assembly and maturation; viral proteases; human immunodeficiency viruses; human cytomegalovirus; respiratory viruses; emerging and re-emerging viruses
Antiviral agents are required for the treatment of viral diseases. Antivirals drugs have been successfully developed and used clinically for a limited number of important human viral diseases, notably, HIV, HCV/HBV, Herpes and influenza infections. These antiviral drugs primarily target a specific viral protein preventing a key step in viral replication, such as viral entry, genome replication, proteolytic processing and assembly/release. Despite the success of these antiviral drugs, issues of drug resistance and toxicity remain challenging. Research on a variety of novel viral targets is ongoing to identify new mechanistic drug classes. Antiviral agents are not available against hundreds of viruses that cause disease in humans; in particular, the development of antiviral agents against emerging and re-emerging viruses is an increasing priority. In addition, traditional drug discovery approaches and strategies targeting host cell factors to develop broadly acting antivirals and combat drug resistance are being explored. Antiviral agents include conventional small molecules and novel agents such as therapeutic antibodies and nucleic acid-based therapies. In this Special Issue, we will focus on existing antiviral agents and related drug resistance, novel viral and host cell targets, new antiviral agents and innovations in drug discovery.
Dr. Catherine Adamson
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antiviral drugs
- broadly acting antivirals
- therapeutic antibodies
- nucleic acid-based therapies
- drug resistance
- drug discovery
- herpes viruses
- emerging and re-emerging viruses